HCM Summit VI offers attendees an opportunity to learn the clinical, morphologic, and genetic spectrum of hypertrophic cardiomyopathy (HCM) from a renowned international faculty.
- Choose contemporary management strategies for high-risk and other patient subgroups, including: surgical septal myectomy, alcohol septal ablation, and prevention of sudden death with implantable defibrillators.
- Outline the causes of sudden death in competitive athletes and the profile of HCM in athlete populations.
- Outline the pros and cons of different mas screening strategies for detecting HCM in general populations.
- Interpret new advances in drug treatment, relief of LV outflow obstruction with novel operative or percutaneous techniques and the potential application of systems biology and personalized medicine to HCM.
21.25 AMA PRA Category 1 Credits™ - maximum
October 27-29, 2017
Boston, Massachusetts 02210, United States